No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC By Ogkologos - September 24, 2026 8 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG/NRG S1914 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems MOST POPULAR Experts Think Medical Detection Dogs Could Be Trained To Sniff Out... March 27, 2020 An unexpected find: clues about the genetics of children’s cancer found... April 6, 2021 Foodie Friday: What to do with all these zucchini? July 9, 2021 Catch up on Behind the Science 2021 – From funding stream... May 17, 2021 Load more HOT NEWS First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2... ΠΩΣ ΠΡΟΚΑΛΕΙΤΑΙ ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib
